Randomized trial demonstrates reduced risk of major adverse cardiovascular events with pitavastatin in HIV infection, highlighting statin efficacy in viral illness.
Participants with HIV infection who received pitavastatin had a lower risk of a major adverse cardiovascular event than those who received placebo over a median follow-up of 5.1 years. (Funded by the National Institutes of Health and others; REPRIEVE ClinicalTrials.gov number, NCT02344290.).
No takes yet. Share an insight, caveat, or question.
Grinspoon et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: